A proven business executive, Chris brings over 24 years of strategy, business development, operations, and marketing to both B to C and B to B organizations of varying sizes. From start-ups to emerging companies to enterprise organizations, Chris has led global marketing, business development and strategic partnerships for several healthcare technology organizations. Chris has deep experience in healthcare technology (Software, Software-as-a-Service, Platform-as-a-Service, Mobile & Services).
Most recently, Chris was the Chief Marketing Officer at Validic where he led global marketing, Business Development and strategic partnership efforts growing Validic to the healthcare industry’s “de facto standard” for accessing data from mobile health devices, wearables, in-home devices and patient healthcare apps. He led the go-to-market initiatives generating 84% of total annual sales revenue.
Prior to that, Chris led Global Marketing at Allscripts, helping to drive dramatic growth ($225M to $1.2B) across several business solutions for physicians, hospitals and post-acute organizations (customer base: 180,000 physicians, 1,500 hospitals, and over 10,000 post-acute organizations around the world). Additionally, Chris has led global Marketing & Strategy in Oral Care technology and Vision Care technology for PE portfolio companies; the work led to successful “event” transactions.
Chris was recently awarded the Chief Marketing Officer Growth Award among over 800 global CMOs, for “demonstrating leadership in new strategies and programs resulting in significant company growth.”
This past year, Chris was a featured thought leader speaker at several major health technology events: Digital Health Summit in Sydney, Australia (keynote), SAP’s Global Innovation Event in Silicon Valley, The Mobile Patient Summit in the Research Triangle Park, NC; Frost & Sullivan’s Digital Transformation Summit; MedTech Summit in Cannes, France; Digital Health Thought Leadership Summit in London.
As healthcare’s conversation platform, Conversa delivers an easy and meaningful way for care teams and patients to communicate. Conversa has an extensive library of over 330 clinically-intelligent conversation programs that include asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension, joint replacement, and many more. Recently Juniper Research stated that “Conversa is the type of company that, through their presence in the market and the kind of product they offer, have the potential to reshape the whole digital health sector. They are an AI company disrupting healthcare in a big way.” Using Conversa’s innovative and scalable Conversational AI technology, healthcare organizations can deliver automated, personalized doctor-patient conversation experiences that lead to more informed and meaningful patient relationships, effective population management and, ultimately, better clinical and financial outcomes. For more information, visit conversahealth.com.